D A M Thuy Trang1,2,3, Koichi Okamura4, Takahito Suto1, Hideo Sakane1, Yukio Yonemoto1, Takahito Nakajima2,5, Yoshito Tsushima2,6, Hirotaka Chikuda1. 1. Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Showamachi 3-39-15, Maebashi, Gunma, 371-8511, Japan. 2. Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Showa-machi 3-39-15, Maebashi, Gunma, 371-8511, Japan. 3. Radiology Center, Bach Mai Hospital, Hanoi, Vietnam. 4. Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Showamachi 3-39-15, Maebashi, Gunma, 371-8511, Japan. kokamura@gunma-u.ac.jp. 5. Department of Diagnostic Radiology and Interventional Radiology, Tsukuba University, Tsukuba, Ibaraki, Japan. 6. Research Program for Diagnostic and Molecular Imaging, Division of Integrated Oncology Research, Gunma University Initiative for Advanced Research (GIAR), Maebashi, Gunma, Japan.
Abstract
OBJECTIVES: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular disease (CVD). In the present study, we evaluated the inflammatory activity of the ascending aorta in RA patients who received biological treatment. METHODS: We assessed the aortic wall inflammation of RA patients using 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography before and after 6 months of biologic therapies. We also compared the inflammatory activity at the aortic wall in RA patients with remission or low disease activity (RLDA) and those with moderate or high disease activity (MHDA). The aortic uptake was measured by the standardized uptake value (SUV) and the target-to-background ratio (TBR). RESULTS: A total of 64 patients were included in the analysis (mean age, 58.4 ± 13.8 years old; female, 77%). The Disease Activity Score for 28 joints (DAS28) erythrocyte sedimentation rate (ESR) had significantly decreased after 6 months: from 5.0 ± 1.2 to 3.3 ± 1.2 (p < 0.001). The FDG uptake in the ascending aorta changed from baseline to 6 months, showing a maximum SUV (SUVmax) of 1.83 ± 0.34 to 1.90 ± 0.34 (p = 0.059) and TBR of 1.71 ± 0.23 to 1.75 ± 0.24 (p = 0.222). The SUVmax and TBR after 6 months were significantly higher in the RLDA group than in the MHDA group (2.05 ± 0.32 vs. 1.79 ± 0.33 (p = 0.002) and 1.89 ± 0.33 vs. 1.65 ± 0.20 (p = 0.001), respectively). The percentage of monocytes also significantly increased from baseline to 6 months: from 5.9 ± 1.6 to 6.9 ± 2.6 (p = 0.032). CONCLUSION: The inflammation activity at the ascending aorta in RA patients did not change significantly after 6 months of biological treatment. RA patients with a low disease activity or in clinical remission after 6 months of biological treatment still had an increased inflammatory activity at the aortic wall.
OBJECTIVES:Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular disease (CVD). In the present study, we evaluated the inflammatory activity of the ascending aorta in RApatients who received biological treatment. METHODS: We assessed the aortic wall inflammation of RApatients using 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography before and after 6 months of biologic therapies. We also compared the inflammatory activity at the aortic wall in RApatients with remission or low disease activity (RLDA) and those with moderate or high disease activity (MHDA). The aortic uptake was measured by the standardized uptake value (SUV) and the target-to-background ratio (TBR). RESULTS: A total of 64 patients were included in the analysis (mean age, 58.4 ± 13.8 years old; female, 77%). The Disease Activity Score for 28 joints (DAS28) erythrocyte sedimentation rate (ESR) had significantly decreased after 6 months: from 5.0 ± 1.2 to 3.3 ± 1.2 (p < 0.001). The FDG uptake in the ascending aorta changed from baseline to 6 months, showing a maximum SUV (SUVmax) of 1.83 ± 0.34 to 1.90 ± 0.34 (p = 0.059) and TBR of 1.71 ± 0.23 to 1.75 ± 0.24 (p = 0.222). The SUVmax and TBR after 6 months were significantly higher in the RLDA group than in the MHDA group (2.05 ± 0.32 vs. 1.79 ± 0.33 (p = 0.002) and 1.89 ± 0.33 vs. 1.65 ± 0.20 (p = 0.001), respectively). The percentage of monocytes also significantly increased from baseline to 6 months: from 5.9 ± 1.6 to 6.9 ± 2.6 (p = 0.032). CONCLUSION: The inflammation activity at the ascending aorta in RApatients did not change significantly after 6 months of biological treatment. RApatients with a low disease activity or in clinical remission after 6 months of biological treatment still had an increased inflammatory activity at the aortic wall.
Authors: Anne G Semb; Silvia Rollefstad; Sella A Provan; Tore K Kvien; Einar Stranden; Inge C Olsen; Jonny Hisdal Journal: J Rheumatol Date: 2013-01-15 Impact factor: 4.666
Authors: Cynthia S Crowson; Katherine P Liao; John M Davis; Daniel H Solomon; Eric L Matteson; Keith L Knutson; Mark A Hlatky; Sherine E Gabriel Journal: Am Heart J Date: 2013-08-29 Impact factor: 4.749
Authors: Carlos Gonzalez-Juanatey; Javier Llorca; Ana Testa; Javier Revuelta; Carlos Garcia-Porrua; Miguel A Gonzalez-Gay Journal: Medicine (Baltimore) Date: 2003-11 Impact factor: 1.889
Authors: Marie-Christine Aubry; Hilal Maradit-Kremers; Megan S Reinalda; Cynthia S Crowson; William D Edwards; Sherine E Gabriel Journal: J Rheumatol Date: 2007-03-15 Impact factor: 4.666
Authors: S Skeoch; P L Hubbard Cristinacce; H Williams; P Pemberton; D Xu; J Sun; J James; C Yuan; T Hatsukami; P D Hockings; M Y Alexander; J C Waterton; I N Bruce Journal: Sci Rep Date: 2017-04-11 Impact factor: 4.379